Literature DB >> 18239405

Upper gastrointestinal Crohn's disease.

Christian Mottet1, Pascal Juillerat, Valérie Pittet, Jean-Jacques Gonvers, Pierre Michetti, John-Paul Vader, Christian Felley, Florian Froehlich.   

Abstract

Symptomatic gastroduodenal manifestations of Crohn's disease are rare, with less than 4% of patients being clinically symptomatic. Gastroduodenal involvement may, however, be found endoscopically in 20% and in up to 40% of cases histologically, most frequently as Helicobacter pylori-negative focal gastritis, usually in patients with concomitant distal ileal disease. In practice, the activity of concomitant distal Crohn's disease usually determines the indication for therapy, except in the presence of obstructive gastroduodenal symptoms. With the few data available, it seems correct to say that localized gastroduodenal disease should be treated with standard medical therapy used for more distal disease, with the exception of the galenic formulation of sulfasalazine and mesalazine with pH-dependent release. The presence of symptoms of obstruction needs aggressive therapy. If medical therapy with steroids and immunomodulatory drugs does not alleviate the symptoms, balloon dilation and surgery are the options to consider. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239405     DOI: 10.1159/000111028

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  9 in total

1.  Recurrent duodenal stricture secondary to untreated Crohn's disease.

Authors:  Timothy A Plerhoples; Jeffrey A Norton
Journal:  Dig Dis Sci       Date:  2012-10       Impact factor: 3.199

2.  Progressive Epigastric Pain with Abnormal Liver Tests in a Patient with Crohn's Disease: Don't DILI Dally.

Authors:  Christina Ling; Michael Gavin; Joshua Hanson; Denis M McCarthy
Journal:  Dig Dis Sci       Date:  2018-07       Impact factor: 3.199

3.  Evidence-based clinical practice guidelines for inflammatory bowel disease.

Authors:  Katsuyoshi Matsuoka; Taku Kobayashi; Fumiaki Ueno; Toshiyuki Matsui; Fumihito Hirai; Nagamu Inoue; Jun Kato; Kenji Kobayashi; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Satoshi Motoya; Masakazu Nagahori; Hiroshi Nakase; Fumio Omata; Masayuki Saruta; Toshiaki Watanabe; Toshiaki Tanaka; Takanori Kanai; Yoshinori Noguchi; Ken-Ichi Takahashi; Kenji Watanabe; Toshifumi Hibi; Yasuo Suzuki; Mamoru Watanabe; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-02-10       Impact factor: 7.527

4.  Major Gastric Haemorrhage After Intragastric Balloon Insertion: Case Report.

Authors:  Romy J Granek; Michael W Hii; Salena M Ward
Journal:  Obes Surg       Date:  2018-01       Impact factor: 4.129

5.  Endoscopic and pathologic changes of the upper gastrointestinal tract in Crohn's disease.

Authors:  Atsushi Sakuraba; Yasushi Iwao; Katsuyoshi Matsuoka; Makoto Naganuma; Haruhiko Ogata; Takanori Kanai; Toshifumi Hibi
Journal:  Biomed Res Int       Date:  2014-02-03       Impact factor: 3.411

Review 6.  Second Korean guidelines for the management of Crohn's disease.

Authors:  Jae Jun Park; Suk-Kyun Yang; Byong Duk Ye; Jong Wook Kim; Dong Il Park; Hyuk Yoon; Jong Pil Im; Kang Moon Lee; Sang Nam Yoon; Heeyoung Lee
Journal:  Intest Res       Date:  2017-01-31

7.  Esophageal Crohn's Disease Unresponsive to Glucocorticoids.

Authors:  Tanureet Kochar; Matthew Krafft; Swapna Gayam
Journal:  ACG Case Rep J       Date:  2019-04-01

8.  Upper gastrointestinal tract involvement of Crohn disease: clinical implications in children and adolescents.

Authors:  Eun Sil Kim; Mi Jin Kim
Journal:  Clin Exp Pediatr       Date:  2021-09-10

9.  The study of gastric mucosa for possible bacterial causative agent of Crohn's disease.

Authors:  Slobodan Kazic; Milena Kazic; Jelena Popovic
Journal:  Iran J Med Sci       Date:  2012-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.